Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper; Mark R. Green; David P. Kelsen; Robert T. Heelan; Thomas D. Brown; Carlos D. Flombaum; Bonnie J. Trochanowski; Peter G. Tarassoff

doi:10.1007/bf00873232

Keywords

GemcitabineMedicineInternal medicineGastroenterologyNucleoside analogueDosingChemotherapyAdenocarcinomaPancreatic cancerToxicitySurgeryClinical trialCancerNucleoside

Affiliated Institutions

Related Publications

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

Giuseppe Colucci , Francesco Giuliani , Vittorio Gebbia +7 more

Abstract BACKGROUND A prospective, randomized Phase III trial was performed to determine whether, compared with gemcitabine (GEM) alone, the addition of cisplatin (CDDP) to GEM ...

2002 Cancer 280 citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann , D. Quietzsch , Frank Gieseler +17 more

Purpose To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic p...

2006 Journal of Clinical Oncology 682 citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Giuseppe Colucci , Roberto Labianca , Francesco Di Costanzo +17 more

Purpose Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo It...

2010 Journal of Clinical Oncology 299 citations

Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate

Caio M. Rocha Lima , Mark R. Green , Robert Rotche +7 more

Purpose This phase III, randomized, open-label, multicenter study compared the overall survival associated with irinotecan plus gemcitabine (IRINOGEM) versus gemcitabine monothe...

2004 Journal of Clinical Oncology 579 citations

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy L. Kindler , Donna Niedzwiecki , Donna Hollis +12 more

Purpose The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metasta...

2010 Journal of Clinical Oncology 834 citations

Publication Info

Year: 1994
Type: article
Volume: 12
Issue: 1
Pages: 29-34
Citations: 440
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

440

OpenAlex

Cite This

APA Style

                            
                                
                                    Ephraim S. Casper, 
                                
                                    Mark R. Green, 
                                
                                    David P. Kelsen
                                
                                et al.
                            
                            (1994). 
                            Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas. 
                            Investigational New Drugs
                            , 12
                            (1)
                            , 29-34.
                            https://doi.org/10.1007/bf00873232
                        

Identifiers

DOI: 10.1007/bf00873232